Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
Foa
R
R
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.
Meloni
G
G
Tosti
S
S
Novarino
A
A
Fenu
S
S
Guarini
A
A
Cardona
S
S
Gillio Tos
A
A
Gavosto
F
F
Mandelli
F
F
D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013921:Thrombocytopenia / Q000209:etiology
D007376:Interleukin-2